Comparing two aneurysm treatments for early complications in people with wide-neck brain aneurysms
Compares early complications of flow diverters and stent-assisted coiling in unruptured wide-neck brain aneurysms.
Plain-language title generated from the registry record
Registry title: Early Complications After Flow Diverter Versus Stent-Assisted Coiling for Unruptured Wide-Neck Intracranial Bifurcation Aneurysms
Key facts
- Where
- Guangzhou, ChinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an unruptured, wide-neck aneurysm at a branching point of a brain artery. It compares two treatments given in routine care: a flow diverter or stent-assisted coiling.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Unruptured, bifurcation, saccular, wide-neck intracranial aneurysm, seen on CTA, MRA, or DSA.
- Earlier treatment
- No stroke in the past 1 month. No surgery or interventional treatment planned within 3 months.
Main reasons for not taking part
- Ruptured or narrow-neck aneurysm
- Two or more aneurysms that all need treatment within 1 year
- Other brain blood vessel disease such as arteriovenous malformation or moyamoya disease
- Modified Rankin Scale score of 3 or more
- Pregnant or breastfeeding women
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07754188, who can take part
Where in China
- Guangdong Province People's HospitalGuangzhou, ChinaContact: Shengpan Chen, MDTaking people
- Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaContact: Wenfeng Feng Feng, Principal Investigator, MDTaking people
- Zhujiang Hospital, Southern Medical UniversityGuangzhou, ChinaContact: Xin Feng, Principal InvestigatorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Nanfang Hospital, Southern Medical University
- Trial code
- NCT07754188
- Record updated
- 10 August 2026
- Original description
This prospective real-world cohort study aims to compare early postoperative complications between flow diverter treatment and stent-assisted coiling in patients with unruptured wide-neck intracranial bifurcation aneurysms. A total of 274 patients from three centers in China will be enrolled and assigned to the flow diverter group or the stent-assisted coiling group according to the treatment received in routine clinical practice. The primary outcome is a composite of any stroke or all-cause death within 30 days after the procedure. The study will also collect demographic, clinical, laboratory, imaging, aneurysm morphological, procedural, and follow-up data to evaluate the safety of these two endovascular treatment strategies in a real-world setting.Read full original descriptionShow less
Early Complications After Flow Diverter Versus Stent-Assisted Coiling for Unruptured Wide-Neck Intracranial Bifurcation Aneurysms: A Prospective Real-World Cohort Study
This prospective real-world cohort study aims to compare early postoperative complications between flow diverter treatment and stent-assisted coiling in patients with unruptured wide-neck intracranial bifurcation aneurysms. A total of 274 patients from three centers in China will be enrolled and assigned to the flow diverter group or the stent-assisted coiling group according to the treatment received in routine clinical practice. The primary outcome is a composite of any stroke or all-cause death within 30 days after the procedure. The study will also collect demographic, clinical, laboratory, imaging, aneurysm morphological, procedural, and follow-up data to evaluate the safety of these two endovascular treatment strategies in a real-world setting.
Inclusion: Voluntarily provides written informed consent; Aged 18 to 75 years; Diagnosed by CTA, MRA, or DSA as having an unruptured, bifurcation, saccular, wide-neck intracranial aneurysm; Able to understand the purpose of the study.
Exclusion: Patients who have already planned to undergo surgical or interventional treatment within 3 months; Patients unable to receive antiplatelet or anticoagulant therapy; Patients with a previous or possible severe reaction to contrast agents that would prevent completion of pre-treatment medication or treatment; Patients who participated in another drug or medical device clinical trial before enrollment and have not reached the time point of the primary endpoint; Patients with other cerebrovascular diseases such as arteriovenous malformation or moyamoya disease; Patients who experienced stroke, including cerebral hemorrhage or cerebral infarction, within the past 1 month; Patients with poor clinical condition, defined as modified Rankin Scale score ≥3; Patients unsuitable for anesthesia or endovascular treatment, including those with major heart, lung, liver, spleen, or kidney disease, brain tumor, severe active infection, disseminated intravascular coagulation, or a history of severe psychiatric disorder; Patients with a known history of allergy to cobalt-chromium or nickel-titanium alloy materials; Patients with two or more multiple aneurysms, all of which require treatment within 1 year; Patients with ruptured aneurysms or narrow-neck aneurysms; Patients considered by the investigator to be unsuitable for endovascular treatment, such as those with no suitable vascular access, excessively tortuous vessels, or difficulty in stent delivery; Pregnant or lactating women; Patients with life expectancy less than 12 months; Patients judged by the investigator to have poor compliance and inability to complete the study as required.